Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Author affiliation: Unidade de Vigilância de Zoonoses da Divisão de Vigilância Ambiental em Saúde, Secretaria Municipal da Saúde, Ribeirão Preto, Brazil (M.J.L. Siconelli); Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto (M.J.L. Siconelli, J.C. de Almeida Dias, B.A. Lopes da Fonseca); Centro de Patologia, Instituto Adolfo Lutz de São Paulo, Secretaria Estadual da Saúde de São Paulo, São Paulo, Brazil (E.F. Machado, N.C.C.A. Fernandes); Centro de Virologia, Instituto Adolfo Lutz de São Paulo, Secretaria Estadual da Saúde de São Paulo, São Paulo (M.S. Cunha); Universidade de São Paulo Departamento de Patologia da Faculdade de Medicina Veterinária e Zootecnia, São Paulo (J.M. Guerra); Programa de Residência em Área Profissional da Saúde, Medicina Veterinária e Saúde, do Departamento de Patologia, Reprodução e Saúde Única da Faculdade de Ciências Agrárias e Veterinárias, Universidade Estadual Paulista, Jaboticabal, Brazil (L. Bonon, A.B. Salomão, K. Werther, K.P. Bürger, A.A.B. Carvalho); Grupo de Vigilância Epidemiológica, Centro de Vigilância Epidemiológica “Prof. Alexandre Vranjac,” Secretaria Estadual da Saúde de São Paulo, São Paulo (D. Marques)

Yellow fever virus (YFV; Orthoflavivirus flavi), is an arbovirus of the Flaviviridae family transmitted by Aedes spp. mosquitoes in the urban cycle and Haemagogus/Sabethes spp. mosquitoes in the sylvatic cycle (1,2). Nonhuman primates (NHPs) are key sentinel animals for early YFV detection and a core component of the Brazilian Yellow Fever Surveillance Program (3). However, YFV pathogenicity varies among species, and the role of Brazil’s diverse NHP populations in continued YFV circulation remains poorly understood (4). Alouatta spp. howler monkeys are the most susceptible to YFV infection (57). Infected NHPs develop clinical and pathologic manifestations similar to those in humans (4,8,9), who exhibit high viral loads and pronounced liver damage, including areas of necrosis and apoptosis, Councilman–Rocha Lima (CRL) bodies, steatosis, and inflammatory infiltrates (10,11).

During 2016–2018, Brazil experienced its worst wild yellow fever outbreak in 70 years, in which most human and NHP cases occurred in the southeastern region (1,2). In that outbreak, most infected NHPs were Callithrix spp. marmosets, revealing 2 infection patterns: one with a high viral load and characteristic histopathologic hepatic lesions and another with low viral loads, absence of clinical disease, and minimal or absent hepatic lesions (4,12).

Figure 1

Figure 1. Location and example species for yellow fever virus (YFV) surveillance in Callithrix spp. marmosets during epizootic outbreak, Brazil, 2024–2025. A) C. penicillatamarmoset. Source: Miguelrangeljr, CC BY-SA…

In 2023, a new YFV lineage emerged in eastern São Paulo state (13), then spread throughout most of the state. The first confirmed NHP deaths attributed to YFV in the region of Ribeirão Preto city occurred in late December 2024. During the following months, the outbreak intensified, and more confirmed NHP infections and 1 human case occurred in the surrounding municipalities (Figure 1). We investigated clinical and laboratory findings of YFV infection among NHPs during that epizootic outbreak.

During July 2024–June 2025, the regional Epidemiologic Surveillance Group reported 233 NHP deaths, of which 79% (184/233) were Callithrix penicillata black-tufted marmosets, 18% (42/233) Alouatta caraya black howler monkeys, 2.15% (5/233) Sapajus nigritus black capuchin monkeys, and 0.85% (2/233) Callicebus nigrifrons black fronted titi monkeys. Among the 233 NHPs, we necropsied and collected biologic samples from 154 (66.1%), 88.9% (n = 137) of which were Callitrichid marmosets.

We confirmed YFV infection in a total of 54 NHPs: 22 by laboratory testing on organ samples collected during necropsy and 32 by epidemiologic criteria. We could not obtain samples from the 32 NHPs identified by epidemiologic criteria because the carcasses were in an advanced state of decomposition. However, we included those animals because they were found in the same epidemiologic context and area in which YFV was detected in other animals.

Figure 2

Figure 2. Laboratory analysis of liver samples from nonhuman primates collected for yellow fever virus (YFV) surveillance in Callithrix spp. marmosets during epizootic outbreak, Brazil, 2024–2025. A, B) Samples from …

Among 22 NHPs with laboratory-confirmed YFV infection, most were A. caraya monkeys (50%; 11/22), followed by C. penicillata (40.9%; 9/22) marmosets and C. nigrifrons (9.1%; 2/22) monkeys. As expected, samples from Alouatta and Callicebus spp. NHPs had low cycle threshold (Ct) values and typical organ lesions, including extensive hepatocellular necrosis, CRL bodies, hepatic steatosis, varying degrees of inflammatory infiltrates, and YFV antigens detectable by immunohistochemistry (IHC) (Figure 2). The YFV-positive marmosets exhibited a consistent pattern: low Ct values (Ct 11.14–20.08), typical histopathologic lesions, and detectable YFV antigens. One marmoset, stored frozen for a month before necropsy, showed a higher Ct value of 28.9.

Figure 3

Figure 3. Laboratory analysis of organ samples collected from Callithrix penicillatamarmosets with severe hepatic lesions due to yellow fever during epizootic yellow fever outbreak, Brazil, 2024–2025. A) Hematoxylin and eosin…

All 9 C. penicillata marmosets were YFV-positive by IHC (Figure 3); 2 (22%) showed advanced autolysis, which precluded evaluation of histopathologic features, but we did detect CRL bodies in 1 of those 2 marmosets. Histopathologic findings in the other 7 animals showed all had hepatic necrosis, 3 (42%) with multifocal panlobular distribution and 4 (57%) with widespread panlobular involvement. Necrosis severity ranged from moderate in 2 (29%) to marked in the other 5 (71%) animals. All 7 animals had CRL bodies, and 3 (43%) had inflammatory infiltrates, consisting of mixed cellular contents in 1 (33.3%) and mononuclear cells in the other 2 (66.7%); we observed multifocal distribution and moderate severity in 2 (66.7%) cases and discrete distribution in 1 (33.3%). We identified hemorrhage in 4 (57%) of those animals, characterized by diffuse distribution in most (75%; 3/4); 3 (75%) exhibited moderate severity and 1 (25%) marked severity. We observed steatosis in 6 (86%) animals and panlobular macrovesicular and microvesicular patterns of moderate severity in 2 (34%) and marked severity in 4 (66%).

During the 2016–2018 outbreak, 7 Callithrix spp. marmosets were YFV-positive, 5 of which were from Ribeirão Preto and neighboring cities, but none had hepatic lesions or YFV antigens detected (14). In 2020, an urban C. penicillata marmoset from midwestern Brazil showed the same pattern, YFV-positive by quantitative reverse transcription PCR but no liver lesions nor YFV antigen detection (15).

The IHC and molecular findings of this study, representing the data from the 2024–2025 epizootic outbreak in São Paulo state demonstrate a consistent pattern of severe acute hepatitis in neotropical primates infected with YFV. All 22 confirmed NHP cases revealed characteristic hepatic lesions, with hepatocellular necrosis in all evaluated specimens, predominantly showing diffuse and multifocal to coalescing patterns. Those findings corroborate previous reports describing panlobular necrosis as a hallmark of fatal YFV infection in primates (4).

We identified CRL bodies, characteristic of YFV lesions, in 80% (18/22) of cases, and noted a much higher frequency in A. caraya and C. nigrifrons monkeys and C. penicillata marmosets. Even in specimens with marked autolysis (typically observed 1–3 days after death) CRL bodies remained detectable in 3 NHPs, reinforcing the strong association of CRL bodies with YFV infections, even under suboptimal tissue preservation conditions. Inflammatory infiltrates were predominantly mixed (polymorphonuclear and mononuclear) or mononuclear, with panlobular or periportal and portal distribution. We observed macrovesicular, microvesicular, or mixed steatosis with diffuse or multifocal distribution and consistent panlobular zonation. Severity was marked to moderate in 72.2% (13/18) of affected animals.

The high prevalence and severity of lesions combined with limited inflammatory response, despite extensive necrosis and steatosis, might indicate a YFV-induced metabolic dysfunction and support YFV as the main mechanism of liver injury. The histopathologic data we present need further investigation because they point to a possible association with the new YFV lineage circulating in southern Brazil. A relevant finding that supports that hypothesis is IHC confirmation of active YFV infection in 100% of cases, including all analyzed C. penicillata marmoset specimens. That contrasts with prior observations during 2017–2018, when Callithrix spp. marmosets often exhibited lower viral loads and milder hepatic lesions (4,14,15). In the NHPs evaluated here, marmosets had severe liver damage comparable to that seen in howler monkeys, with extensive necrosis and unequivocal IHC positivity. The severe lesions observed in Callithrix spp. marmosets underscore this primate’s relevance in NHP-based YFV surveillance, particularly in areas where Alouatta spp. monkey populations have been greatly reduced.

Our results confirm the classic histopathologic profile of YFV infection in neotropical primates, with striking severity in C. penicillata marmosets during an outbreak in an area with reduced Alouatta spp. monkey populations. The combination of hepatocellular necrosis, CRL bodies, steatosis, and 100% IHC positivity provides robust evidence for YFV pathogenicity across multiple primate species and reinforces the need for continuous surveillance in NHPs, placing Callithrix genus NHPs under the public health spotlight in this and in future epidemics. Its ability to adapt to urbanized environments, its proximity to humans, and the high Ae. aegypti mosquito population raise concerns for yellow fever reurbanization.

Our findings underscore the need for establishing a new NHP surveillance system based on Callithrix spp. marmosets in areas where Alouatta spp. monkey populations have been reduced or extinguished. Therefore, local zoonotic surveillance services in high-risk areas must be strengthened to detect early YFV circulation in the face of current NHP deaths, especially in view of a possible change in the yellow fever epidemiologic pattern.

About the Author

Dr. Siconelli is veterinarian specialized in zoonotic diseases at Unidade de Vigilância de Zoonoses da Divisão de Vigilância Ambiental em Saúde, Brazil. His research interests focus on surveillance programs with emphasis on arboviruses, particularly yellow fever virus and West Nile virus.

Author contributions: M.J.L.S. conceptualized, devised methodology, conducted investigations, curated data, co-wrote the first draft and reviewed and edited subsequent drafts, and was responsible for project administration and acquiring funding; J.C.A.D. conducted investigations and processed samples; E.F.M. curated data, co-wrote the first draft, and reviewed and edited subsequent drafts; M.S.C., N.C.C.A.F., and J.M.G. conducted investigations, processed samples, and reviewed and edited manuscript drafts; L.B. and A.B.S. participated ins investigations and sample collection; K.W., K.P.B., A.A.B.C., and D.M. reviewed and edited manuscript drafts. B.A.L.F. supervised, conceptualized, devised methodology, and provided resources for the study, reviewed and edited manuscript drafts, served as project administrator, and acquired funding. All authors read, reviewed and approved the final version of the manuscript.

Top

Source

Clinical :: Oncology :: Nuclear :: Geriatric :: Regulatory :: Technology :: Consulting

"My passion is helping businesses, small and large, perform at their best." - Felicia Udoji-Eddings, Pharm.D.

Dr. Felicia Udoji-Eddings is the Founder and CEO of The Health Pals Company, a vertically integrated Healthcare System. As an experienced Clinical Pharmacy Leader, Pharmacy Consultant, Healthcare Executive, and Licensed Pharmacy Practitioner with deep backgrounds in Information Technology (IT), Scientific Research, and Business Management. Dr. Udoji-Eddings has a strong track record of exceptional performance in different business environments. A skilled Business Strategist, Dr. Udoji-Eddings has tackled complex problems and helped several organizations refocus their strategy in tough economic times. As a highly motivated and proactive individual, Felicia enjoys working with teams, in various capacities, to facilitate positive outcomes.